Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 311-321

  Kalliokoski, Annikka ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Nateglinide; OATP1B1; Pharmacogenetics; Repaglinide; SLCO1B1

Indexed keywords

DRUG METABOLITE; GLUCOSE; NATEGLINIDE; ORGANIC ANION TRANSPORTER 2; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE DRUG DOSE;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CARBAMATES; CHROMATOGRAPHY, LIQUID; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; PHENYLALANINE; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 39149108768     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007311569     Document Type: Article

References (47)

1. Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001 ; 358: 1709-1716.
2. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002 ; 41: 471-483.
3. McLeod JF Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet. 2004 ; 43: 97-120.
4. Bidstrup TB, Bjørnsdottir I., Sidelmann UG, Thomsen MS, Hansen KT CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003 ; 56: 305-314.
5. Kajosaari LI, Laitila J., Neuvonen PJ, Backman JT Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005 ; 97: 249-256.
6. Takesada H., Matsuda K., Ohtake R., et al. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent. Bioorg Med Chem. 1996 ; 4: 1771-1781.
7. Niemi M., Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003 ; 42: 819-850.
8. Bidstrup TB, Stilling N., Damkier P., Scharling B., Thomsen MS, Brøsen K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol. 2004 ; 60: 109-114.
9. Vavricka SR, Van Montfoort J., Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 ; 36: 164-172.
10. Hagenbuch B., Meier PJ Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature, and molecular/ functional properties. Pflugers Arch. 2004 ; 447: 653-665.
11. Hsiang B., Zhu Y., Wang Z., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 ; 274: 37161-37168.
12. Shitara Y., Itoh T., Sato H., Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 ; 304: 610-616.
13. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 ; 311: 139-146.
14. Kameyama Y., Yamashita K., Kobayashi K., Hosokawa M., Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15, and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 ; 15: 513-522.
15. Kopplow K., Letschert K., König J., Walter B., Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 ; 68: 1031-1038.
16. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 ; 130: 1793-1806.
17. Yamashiro W., Maeda K., Hirouchi M., Adachi Y., Hu Z., Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 ; 34: 1247-1254.
18. Nakagomi-Hagihara R., Nakai D., Kawai K., et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 ; 34: 862-869.
19. Sandhu P., Lee W., Xu X., et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 ; 33: 676-682.
20. Nozawa T., Minami H., Sugiura S., Tsuji A., Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005 ; 33: 434-439.
21. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007 ; 8: 787-802.
22. Tirona RG, Leake BF, Merino G., Kim RB Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001 ; 276: 35669-35675.
23. Michalski C., Cui Y., Nies AT, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem. 2002 ; 277: 43058-43063.
24. Niemi M., Schaeffeler E., Lang T., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 ; 14: 429-440.
25. Nishizato Y., Ieri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 ; 73: 554-565.
26. Niemi M., Pasanen MK, Neuvonen PJ SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 ; 80: 356-366.
27. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 ; 78: 330-341.
28. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005 ; 78: 342-350.
29. Pasanen MK, Neuvonen M., Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 ; 16: 873-879.
30. Pasanen MK, Fredrikson H., Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007 ; 82: 726-733.
31. Niemi M., Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 ; 77: 468-478.
32. Zhang W., He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 2006 ; 62: 567-572.
33. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 2006 ; 62: 409-415.
34. Nozawa T., Nakajima M., Tamai I., et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002 ; 302: 804-813.
35. Maeda K., Ieri I., Yasuda K., et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006 ; 79: 427-439.
36. Mwinyi J., Johne A., Bauer S., et al. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004 ; 75: 415-421.
37. Niemi M., Leathart JB, Neuvonen M., Backman JT, Daly AK, Neuvonen PJ Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003 ; 74: 380-387.
38. Bidstrup TB, Damkier P., Olsen AK, Ekblom M., Karlsson A., Brøsen K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol. 2006 ; 61: 49-57.
39. Kirchheiner J., Meineke I., Müller G., et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004 ; 43: 267-278.
40. Stephens M., Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001 ; 68: 978-989.
41. Stephens M., Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003 ; 73: 1162-1169.
42. Kajosaari LI, Niemi M., Backman JT, Neuvonen PJ Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006 ; 79: 231-242.
43. Niemi M., Neuvonen M., Juntti-Patinen L., Backman JT, Neuvonen PJ Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther. 2003 ; 74: 25-31.
44. Niemi M., Backman JT, Neuvonen M., Neuvonen PJ, Kivistö KT Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 2000 ; 68: 495-500.
45. Niemi M., Backman JT, Neuvonen M., Neuvonen PJ Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br J Clin Pharmacol. 2003 ; 56: 427-432.
46. Kajosaari LI, Niemi M., Neuvonen M., Laitila J., Neuvonen PJ, Backman JT Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005 ; 78: 388-399.
47. van Heiningen PN, Hatorp V., Kramer Nielsen K, et al. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. Eur J Clin Pharmacol. 1999 ; 55: 521-525.